ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105. A total of 113 filers reported holding ACLARIS THERAPEUTICS INC in Q1 2017. The put-call ratio across all filers is - and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $25,282,254 | -13.2% | 3,690,840 | +31.5% | 0.01% | -16.7% |
| Q2 2023 | $29,111,431 | +7.1% | 2,807,274 | -16.5% | 0.01% | 0.0% |
| Q1 2023 | $27,191,007 | +58.9% | 3,361,064 | +209.4% | 0.01% | +50.0% |
| Q4 2022 | $17,111,430 | -2.8% | 1,086,440 | -2.9% | 0.00% | 0.0% |
| Q3 2022 | $17,603,000 | +32.3% | 1,118,417 | +17.3% | 0.00% | +33.3% |
| Q2 2022 | $13,305,000 | -20.6% | 953,072 | -2.0% | 0.00% | 0.0% |
| Q1 2022 | $16,761,000 | +11.7% | 972,200 | -5.8% | 0.00% | 0.0% |
| Q4 2021 | $15,012,000 | -24.7% | 1,032,472 | -6.8% | 0.00% | -25.0% |
| Q3 2021 | $19,942,000 | -11.3% | 1,107,917 | -13.5% | 0.00% | -20.0% |
| Q2 2021 | $22,488,000 | -37.2% | 1,280,593 | -9.9% | 0.01% | -37.5% |
| Q1 2021 | $35,805,000 | +4347.8% | 1,420,849 | +1041.8% | 0.01% | – |
| Q4 2020 | $805,000 | +689.2% | 124,442 | +215.8% | 0.00% | – |
| Q3 2020 | $102,000 | +92.5% | 39,404 | -23.1% | 0.00% | – |
| Q1 2020 | $53,000 | +3.9% | 51,250 | +91.4% | 0.00% | – |
| Q4 2019 | $51,000 | -36.2% | 26,771 | -64.2% | 0.00% | – |
| Q3 2019 | $80,000 | +12.7% | 74,734 | +130.3% | 0.00% | – |
| Q2 2019 | $71,000 | -93.7% | 32,453 | -82.8% | 0.00% | -100.0% |
| Q1 2019 | $1,131,000 | -72.4% | 188,841 | -65.9% | 0.00% | -50.0% |
| Q4 2018 | $4,096,000 | -68.0% | 554,338 | -37.2% | 0.00% | -66.7% |
| Q3 2018 | $12,812,000 | -26.1% | 882,364 | +1.6% | 0.01% | -33.3% |
| Q2 2018 | $17,339,000 | +10.4% | 868,230 | -3.2% | 0.01% | 0.0% |
| Q1 2018 | $15,712,000 | +329.3% | 896,837 | +504.3% | 0.01% | +350.0% |
| Q4 2017 | $3,660,000 | -41.4% | 148,415 | -38.7% | 0.00% | -60.0% |
| Q3 2017 | $6,247,000 | +585.7% | 242,016 | +620.6% | 0.01% | +400.0% |
| Q2 2017 | $911,000 | -40.0% | 33,587 | -34.1% | 0.00% | 0.0% |
| Q1 2017 | $1,519,000 | +538.2% | 50,944 | +447.6% | 0.00% | – |
| Q3 2016 | $238,000 | – | 9,303 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management V, LLC | 1,258,243 | $8,618,965 | 13.75% |
| Foresite Capital Management IV, LLC | 2,808,034 | $19,235,033 | 10.68% |
| Bain Capital Life Sciences Investors, LLC | 3,400,000 | $23,290,000 | 2.60% |
| GREAT POINT PARTNERS LLC | 1,691,768 | $11,588,611 | 2.11% |
| Samsara BioCapital, LLC | 696,171 | $4,768,771 | 1.46% |
| Altium Capital Management LP | 403,000 | $2,760,550 | 1.44% |
| BVF INC/IL | 7,064,736 | $48,393,442 | 1.30% |
| Aisling Capital Management LP | 434,455 | $2,976,017 | 1.23% |
| GREAT POINT PARTNERS LLC | 700,000 | $4,795,000 | 0.87% |
| VR Adviser, LLC | 1,040,754 | $7,129,165 | 0.75% |